Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sB24M
- Development stage
- Phase 1
- Lead developer
- SWISS BIOPHARMA MED
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Topical, Local Injection
01
Overview
sB24M is a monoclonal antibody developed as a protein-based therapy using biotechnology methods. It acts as an inhibitor and modulator of the CD47 and tumor necrosis factor (TNF, specifically TNF-α) pathways. The drug is designed to negatively regulate immune-inflammatory processes through the CD47/TNF-α axis, thereby promoting epithelialization and healing of damaged tissue. Its primary clinical development has focused on topical or local injection for severe forms of pyoderma gangrenosum, a rare skin disease characterized by chronic ulcerative lesions. The drug was initially developed by SWISS BIOPHARMA MED GmbH[1][2][4].
- Other names
- Monoclonal antibody (Mab) sB24M
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))CD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on sB24M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sB24M.